Comparison of the Effects of Levamlodipine Besylate Tablets and Nifedipine Controlled-release Tablets in the Treatment of Essential Hypertension
WAN Qifang
Abstract：Objective: To compare the efficacy of amlodipine besylate tablets and nifedipine controlled-release tablets in the treatment of primary hypertension. Methods: A total of 200 patients with primary hypertension admitted to our hospital from July 2021 to August 2023 were randomly divided into two groups using a random number table method, with 100 patients in each group. The nifedipine group was treated with nifedipine controlled-release tablets, while the amlodipine besylate group was treated with amlodipine besylate tablets. The clinical efficacy and safety of the two groups were compared. Results: There was no significant difference in blood pressure between the two groups before treatment (P > 0.05). After treatment, the blood pressure of both groups decreased compared to before, and the amlodipine besylate group had lower blood pressure than the nifedipine group (P < 0.05). The incidence of adverse reactions in the amlodipine besylate group was lower than that in the nifedipine group (P < 0.05). Conclusion: Compared with nifedipine controlled-release tablets, amlodipine besylate shows its superiority in treating primary hypertension, significantly reducing systolic and diastolic blood pressure, with fewer adverse reactions and higher safety, which has promotional value.
Keywords：HypertensionLevamlodipine besylate tabletsNifedipine controlled-release tabletsSystolic blood pressureDiastolic blood pressure
Publication Date：2025-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 16-18 )